![Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial](https://oncodaily.com/pub/uploads/2024/06/kiladjian-e1718469389609-1280x721.jpg)
Photo taken from
Gonzalo Carreño Gómez-Tarragona/X
Jun 17, 2024, 01:15
Jean-Jacques Kiladjian: The new findings of Proud-Continuation PV randomized trial
Jean-Jacques Kiladjian, Professor of Clinical Pharmacology at Paris Diderot University, shared a post on X:
“Don’t miss the new findings of Proud-Continuation PV randomized trial showing the correlation between JAK2 mutation reduction with ropeginterferon alpha 2b and better event-free survival!
Molecular response is a meaningful goal of therapy in PV.”
Source: Jean-Jacques Kiladjian/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 11, 2024, 05:25
Sep 11, 2024, 04:28
Sep 11, 2024, 01:59
Sep 10, 2024, 18:47